Association Between Inflammatory Biomarkers and Venous Thromboembolism: a Systematic Review and Meta-analysis

Overview

Journal Thromb J

Publisher Biomed Central

Date 2023 Jul 31

PMID 37525162

Authors

Jiayue Ding

Xuanye Yue

Xiaobing Tian

Zhangyuan Liao

Ran Meng

Ming Zou

Affiliations

Soon will be listed here.

Abstract

Background: Venous thromboembolism (VTE) is a common thrombotic vascular disease that has a significant impact on people's well-being and quality of life. A plethora of clinical studies explore the relationship between inflammatory biomarkers and VTE but yield conflicting results. This article proposed to pool these studies to draw a more convincing conclusion.

Methods: We searched several databases for studies before April 2023. Available data was processed using Stata software (version 15.0 SE) and R (version 4.1.2). This meta-analysis has been registered in PROSPERO (CRD42022321815). The VTE in this review encompassed pulmonary embolism, deep vein thrombosis, and cerebral venous thrombosis.

Results: A total of 25 articles were finally involved in this study. Our results revealed that higher levels of high-sensitivity C-reactive protein (hs-CRP, MD, 0.63, 95%CI, 0.21-1.05) and C-reactive protein (CRP)> 3ug/ml (OR, 1.52, 95%CI, 1.18-1.96) might be regarded as risk factors for future VTE occurrence. The elevated levels of monocyte (MD, 0.03, 95%CI, 0.00-0.05), hs-CRP (0.85, 0.61-1.08), CRP (0.66, 0.20-1.13) and IL-6 (0.47, 0.25-0.70) might represent the previous VTE; a series of markers such as white blood cell (1.43, 0.88-1.98), neutrophil (1.79, 1.02-2.56), monocyte (0.17, 0.14-0.21), hs-CRP (3.72, 1.45-5.99), IL-6 (5.99, 4.52-7.46), platelet-lymphocyte ratio (33.1, 24.45-41.78) and neutrophil-lymphocyte ratio (1.34, 0.95-1.73) increased during the acute phase of VTE.

Conclusions: In general, activated inflammatory biomarkers might not only be correlated with an increased risk of VTE, but may also give a hint of the occurrence of VTE in clinical settings.

Citing Articles

Evaluation of direct oral anticoagulant continuation versus switching to a parenteral anticoagulant in critically ill patients: a retrospective cohort study.

Alshehri A, Alrashed M, Alzahrani M, Alsuwaylihi A, Alarifi A, Althobiti F Thromb J. 2025; 23(1):20.

PMID: 40065356 PMC: 11892205. DOI: 10.1186/s12959-025-00703-1.

Association between neutrophile-to-lymphocyte ratio and risk of deep vein thrombosis in patient receiving lower extremity orthopedic surgery: A meta-analysis.

Chen I, Wang W, Hung K PLoS One. 2025; 20(2):e0319107.

PMID: 39993008 PMC: 11849845. DOI: 10.1371/journal.pone.0319107.

Prognostic Nutritional Index as a Potential Biomarker for the Risk of Lower Extremity Deep Venous Thrombosis: A Large Retrospective Study.

Wang H, Zhou Q, Wang Z, Chen X, Wu Y, Liu M Clin Appl Thromb Hemost. 2025; 31:10760296251317520.

PMID: 39945028 PMC: 11822822. DOI: 10.1177/10760296251317520.

D-dimers or more? Assessing the role of laboratory factors in predicting and confirming pulmonary embolism in high-risk orthopedic patients.

Borowski B, Haratym M, Piech P, Jarecki J, Staskiewicz G Pract Lab Med. 2025; 44:e00452.

PMID: 39945000 PMC: 11815958. DOI: 10.1016/j.plabm.2025.e00452.

The Prognostic Value of Inflammatory Indices in Acute Pulmonary Embolism.

Haba M, Manole O, Buburuz A, Tudorancea I, Costache-Enache I, Onofrei V Diagnostics (Basel). 2025; 15(3).

PMID: 39941242 PMC: 11817101. DOI: 10.3390/diagnostics15030312.

References

Zakai N, Wright J, Cushman M . Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004; 2(12):2156-61. DOI: 10.1111/j.1538-7836.2004.00991.x. View

Eylev Akboga Y, Bektas H, Anlar O . Usefulness of platelet to lymphocyte and neutrophil to lymphocyte ratios in predicting the presence of cerebral venous sinus thrombosis and in-hospital major adverse cerebral events. J Neurol Sci. 2017; 380:226-229. DOI: 10.1016/j.jns.2017.07.036. View

Wang L, Duan J, Bian T, Meng R, Wu L, Zhang Z . Inflammation is correlated with severity and outcome of cerebral venous thrombosis. J Neuroinflammation. 2018; 15(1):329. PMC: 6260678. DOI: 10.1186/s12974-018-1369-0. View

Lowe G, Rumley A, Woodward M, Vessey M . C-reactive protein, idiopathic venous thromboembolism and hormone replacement therapy. Thromb Haemost. 2000; 84(4):730-1. View

Folsom A, Lutsey P, Heckbert S, Poudel K, Basu S, Hoogeveen R . Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism. J Thromb Haemost. 2018; 16(10):1964-1972. PMC: 6173641. DOI: 10.1111/jth.14241. View

Ding J, Song B, Xie X, Li X, Chen Z, Wang Z . Inflammation in Cerebral Venous Thrombosis. Front Immunol. 2022; 13:833490. PMC: 9013750. DOI: 10.3389/fimmu.2022.833490. View

Saghazadeh A, Hafizi S, Rezaei N . Inflammation in venous thromboembolism: Cause or consequence?. Int Immunopharmacol. 2015; 28(1):655-65. DOI: 10.1016/j.intimp.2015.07.044. View

Vormittag R, Vukovich T, Schonauer V, Lehr S, Minar E, Bialonczyk C . Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb Haemost. 2005; 93(3):488-93. DOI: 10.1160/TH04-11-0745. View

Zacho J, Tybjaerg-Hansen A, Nordestgaard B . C-reactive protein and risk of venous thromboembolism in the general population. Arterioscler Thromb Vasc Biol. 2010; 30(8):1672-8. DOI: 10.1161/ATVBAHA.109.198473. View

10.

Yang W, Liu Y . Platelet-lymphocyte ratio is a predictor of venous thromboembolism in cancer patients. Thromb Res. 2014; 136(2):212-5. DOI: 10.1016/j.thromres.2014.11.025. View

11.

Xu G, Liu X, Zhu W, Yin Q, Zhang R, Fan X . Feasibility of treating hyperfibrinogenemia with intermittently administered batroxobin in patients with ischemic stroke/transient ischemic attack for secondary prevention. Blood Coagul Fibrinolysis. 2007; 18(2):193-7. DOI: 10.1097/MBC.0b013e328040c0f2. View

12.

Farah R, Nseir W, Kagansky D, Khamisy-Farah R . The role of neutrophil-lymphocyte ratio, and mean platelet volume in detecting patients with acute venous thromboembolism. J Clin Lab Anal. 2019; 34(1):e23010. PMC: 6977138. DOI: 10.1002/jcla.23010. View

13.

Engelmann B, Massberg S . Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol. 2012; 13(1):34-45. DOI: 10.1038/nri3345. View

14.

Kelly P, Lemmens R, Tsivgoulis G . Inflammation and Stroke Risk: A New Target for Prevention. Stroke. 2021; 52(8):2697-2706. DOI: 10.1161/STROKEAHA.121.034388. View

15.

Tekesin A, Tunc A . Inflammatory markers are beneficial in the early stages of cerebral venous thrombosis. Arq Neuropsiquiatr. 2019; 77(2):101-105. DOI: 10.1590/0004-282X20190001. View

16.

Luo D, Wan X, Liu J, Tong T . Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2016; 27(6):1785-1805. DOI: 10.1177/0962280216669183. View

17.

Ramacciotti E, Blackburn S, Hawley A, Vandy F, Ballard-Lipka N, Stabler C . Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost. 2011; 17(4):425-31. PMC: 3306250. DOI: 10.1177/1076029611405032. View

18.

Poredos P, Jezovnik M . In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels. 2011; 26(6):596-602. DOI: 10.1007/s00380-010-0111-3. View

19.

Sharma D, Spring K, Bhaskar S . Neutrophil-lymphocyte ratio in acute ischemic stroke: Immunopathology, management, and prognosis. Acta Neurol Scand. 2021; 144(5):486-499. DOI: 10.1111/ane.13493. View

20.

Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View